Unjoni Ewropea - Spanjol - EMA (European Medicines Agency)

teva pharma b.v. - docetaxel - carcinoma, non-small-cell lung; breast neoplasms; prostatic neoplasms - agentes antineoplásicos - mama cancerdocetaxel teva pharma monoterapia está indicado para el tratamiento de pacientes con localmente avanzado o metastásico, cáncer de mama, después del fracaso de la terapia citotóxica. la quimioterapia anterior debería haber incluido una antraciclina o un agente alquilante. no de células pequeñas de pulmón cancerdocetaxel teva pharma está indicado para el tratamiento de pacientes con localmente avanzado o metastásico de células no pequeñas de cáncer de pulmón después del fracaso de la quimioterapia previa. docetaxel teva pharma en combinación con cisplatino está indicado para el tratamiento de pacientes con resecable, localmente avanzado o metastásico de células no pequeñas de cáncer de pulmón, en pacientes que no han recibido previamente quimioterapia para esta enfermedad. la próstata cancerdocetaxel teva pharma en combinación con prednisona o prednisolona está indicado para el tratamiento de pacientes con hormona de cáncer de próstata metastásico resistente.

Spanja - Spanjol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ratiopharm espana s.a. - simvastatina; ezetimiba - comprimido - 20 mg/10 mg - simvastatina 20 mg; ezetimiba 10 mg - simvastatina y ezetimiba

Spanja - Spanjol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

bluepharma industria farmaceutica s.a. - alendronico acido; colecalciferol - comprimido - 70 mg/5.600 ui - alendronico acido 70 mg; colecalciferol 5600 ui - Ácido alendrónico y colecalciferol

Spanja - Spanjol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

bluepharma industria farmaceutica s.a. - alendronico acido; colecalciferol - comprimido - 70 mg/2.800 ui - alendronico acido 70 mg; colecalciferol 2800 ui - Ácido alendrónico y colecalciferol

Spanja - Spanjol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

teva pharma s.l.u. - vardenafilo hidrocloruro trihidrato - comprimido bucodispersable - 10 mg - vardenafilo hidrocloruro trihidrato 10 mg - vardenafilo

Spanja - Spanjol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

chanelle pharmaceutical manufacturing ltd. - moxidectina - soluciÓn oral - - moxidectina - ovino

Spanja - Spanjol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ratiopharm espana s.a. - febuxostat - comprimido recubierto con pelÍcula - 80 mg - febuxostat 80 mg - febuxostat

Spanja - Spanjol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

neuraxpharm spain s.l. - desvenlafaxina benzoato - comprimido de liberaciÓn prolongada - 100 mg - desvenlafaxina benzoato 100 mg - desvenlafaxina

Spanja - Spanjol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

neuraxpharm spain s.l. - desvenlafaxina benzoato - comprimido de liberaciÓn prolongada - 50 mg - desvenlafaxina benzoato 50 mg - desvenlafaxina

Unjoni Ewropea - Spanjol - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - agentes antineoplásicos - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq como monoterapia está indicado para el tratamiento de pacientes adultos con localmente avanzado o metastásico de pulmón no microcítico después de la quimioterapia previa. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq como monoterapia está indicado para el tratamiento de pacientes adultos con localmente avanzado o metastásico de pulmón no microcítico después de la quimioterapia previa. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.